Latest News

The Dangers of Inhalant Use Disorder
The Dangers of Inhalant Use Disorder

October 17th 2024

Inhalant use disorder is a form of substance use disorder characterized by the intentional inhalation of volatile substances for their psychoactive effects.

cocaine
A Randomized Controlled Trial of Lorcaserin in Cocaine Use Disorder

October 7th 2024

Adolescent Pregnancy and Parenting: Reducing Stigma and Improving Outcomes
Adolescent Pregnancy and Parenting: Reducing Stigma and Improving Outcomes

September 26th 2024

nitrous oxide
Galaxy Gas: The Dangerous Viral Trend

September 24th 2024

end of life
End-of-Life Care for Patients With Psychiatric Disorders

September 20th 2024

Latest CME Events & Activities

2023 Annual Psychiatric Times™ World CME Conference

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Real Psychiatry 2025

January 17 - 18, 2025

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

More News

© 2024 MJH Life Sciences

All rights reserved.